Triggers and cues that activate antibiotic production by actinomycetes

Hua Zhu · Stephanie K. Sandiford ·
Gilles P. van Wezel

Received: 7 May 2013 / Accepted: 30 June 2013 / Published online: 2 August 2013
© Society for Industrial Microbiology and Biotechnology 2013

Abstract Actinomycetes are a rich source of natural products, and these mycelial bacteria produce the majority of the known antibiotics. The increasing difficulty to find new drugs via high-throughput screening has led to a decline in antibiotic research, while infectious diseases associated with multidrug resistance are spreading rapidly. Here we review new approaches and ideas that are currently being developed to increase our chances of finding novel antimicrobials, with focus on genetic, chemical, and ecological methods to elicit the expression of biosynthetic gene clusters. The genome sequencing revolution identified numerous gene clusters for natural products in actinomycetes, associated with a potentially huge reservoir of unknown molecules, and prioritizing them is a major challenge for in silico screening-based approaches. Some antibiotics are likely only expressed under very specific conditions, such as interaction with other microbes, which explains the renewed interest in soil and marine ecology. The identification of new gene clusters, as well as chemical elicitors and culturing conditions that activate their expression, should allow scientists to reinforce their efforts to find the necessary novel antimicrobial drugs.

Keywords Silent antibiotic · Elicitor · Soil ecology · Natural product · Genome mining · *Streptomyces*

Introduction

The discovery of penicillin by Sir Alexander Fleming [42] opened up a completely new era of chemotherapy. The discovery of numerous antibiotics from primarily soil microorganisms and the near eradication of diseases such as tuberculosis led to the concept that infectious diseases may be something of the past [53]. However, the emergence of infectious diseases involving multidrug resistant (MDR) bacterial pathogens since the 1980s means that bacterial infections are still a major threat for human health. According to the World Health Organization (WHO), around 440,000 new cases of multidrug-resistant tuberculosis (MDR-TB) are found annually, causing more than 150,000 deaths. Extensively drug-resistant tuberculosis (XDR-TB) has now been reported in 64 countries to date [159]. The explosive increase in infections by pathogens such as methicillin-resistant *Staphylococcus aureus* (MRSA), vancomycin-resistant *Enterococcus faecium* (VRE) and fluoroquinolone-resistant *Pseudomonas aeruginosa* is estimated to cause approximately 19,000 deaths per year in the US [70], and the most recent occurrence of pan-antibiotic-resistant infections pose the grave threat of completely untreatable infections [8].

Filamentous microorganisms (fungi and bacteria of the order of Actinomycetales) are the major source of secondary metabolites, producing some 90 % of all known antibiotics [15, 100]. Some two-thirds of all antibiotics are produced by actinomycetes, the majority of which by members of the genus *Streptomyces*. Until now, tens of thousands of natural antimicrobial products have been isolated from microbial sources, and still these likely represent only a tiny portion of the repertoire of bioactive compounds that can potentially be produced [15, 100]. Also, the microbial biodiversity of soil and marine

Special issue: Genome Mining for Natural Products Discovery.

H. Zhu · S. K. Sandiford · G. P. van Wezel (✉)
Molecular Biotechnology, Institute of Biology, Leiden
University, Sylviusweg 72, 2333 BE Leiden, The Netherlands
e-mail: g.wezel@biology.leidenuniv.nl

environments is enormous, with millions of fungi and bacteria likely to be present, of which we have seen only the tip of the iceberg [119].

The decline of high-throughput screening of antibiotics and silent gene clusters

As early as the 1990s, it was predicted that the future of antibiotic discovery might not lie in high-throughput screening (HTS; [71]) or combinatorial chemistry [97]. Perhaps the best known example is the HTS effort conducted by GlaxoSmithKline, where millions of compounds were screened in many HTS campaigns, with only marginal success [117]. Underlying causes for the lack of success include the fact that many of the essential targets in the bacterial cell are not “druggable”, that the molecules identified by HTS do not always have the ideal drug properties as defined in Lipinski’s rule-of-five [78], and that molecules in compound libraries are biased for use in pharmacology and do not have the molecular complexity of naturally occurring secondary metabolites.

Antibiotics not yet discovered have been estimated to be produced at frequencies of less than one per million in fermentation broths from randomly chosen actinomycetes [10, 12]. The situation is often hindered by the fact that often actinomycetes produce high levels of several antibiotics, which will obscure the production of less well expressed or less bioactive antibiotics. How can we stand a chance to find anything novel when BigPharma fails to find them in their comprehensive screening efforts? For one, actinomycetes are soil or marine bacteria, and one approach most likely lies in the direction of ecology. In other words, if we understand the temporal and conditional cues that activate antibiotic production in situ, this can then be applied to improve screening efforts. A second aspect that is now available is the information derived from whole genome sequencing and the connected genomics technologies. Sequencing the genomes of actinomycetes established the presence of many more biosynthetic clusters for secondary metabolites than originally anticipated. For example, it has been known for decades from the pioneering work of David Hopwood and many of his colleagues that the model actinomycete *Streptomyces coelicolor* produces four antibiotics, namely actinorhodin (Act), undecylprodigiosin (Red), calcium-dependent antibiotic (Cda), and the plasmid-encoded methylenomycin (Mmy) [51, 53]. Still, despite 50 years of intensive research, it came as a complete surprise when the *S. coelicolor* genome sequence [14] revealed the presence of many previously unidentified biosynthetic gene clusters [25, 53], including one for a likely antibiotic called cryptic polyketide (Cpk; [116]). It rapidly became clear that other actinomycetes also have extensive arsenals of secondary

metabolites [59, 109, 111, 112, 147]. It therefore appears that the potential of these organisms for novel drug production is much larger than originally anticipated. This has led to extensive research into the applied genomics relating to what is generally referred to as cryptic, silent, or sleeping antibiotics (reviewed in [46, 94, 99, 152, 169]).

Therefore, there are likely many yet-unidentified compounds out there, which were missed either because the gene clusters that specify them are not expressed at sufficiently high levels or because the compounds have lower specific activity than the readily screenable antibiotics and may require modification to become more active. Here we review in particular global approaches for antibiotic mining, with the activation of poorly expressed antibiotic biosynthetic gene clusters in mind.

Regulation of antibiotic production

The regulation of antibiotic production involves multiple regulatory cascades and networks. Knowledge on the regulatory genes can be applied in approaches to activate antibiotic production but is also very useful in terms of localizing biosynthetic gene clusters (see below). Although the number and variety of genes involved vary from species to species, certain features are common. Global regulators almost by definition have a wide-ranging impact on global transcription patterns, but also “cluster-situated regulators” (CSRs) may have a broader impact than only on the cluster they are associated with [58]. Genes involved in antibiotic production are generally organized in biosynthetic gene clusters, consisting of several transcription units. Besides the obvious advantage of coordinated control of biosynthesis, export, and resistance, the additional evolutionary driving force behind such linkage is most likely an ecological one, as it allows the transfer of complete gene clusters during genetic exchange in the habitat.

The *act* gene cluster as model system

Arguably the best studied antibiotic gene cluster is *act* in *S. coelicolor*, for the type-II PKS actinorhodin (Act). This genetic system is a beautiful illustration of the possible complexity of the regulatory networks involved in the control of antibiotic production, and we highlight common features to illustrate the relevant concepts, in particular because most pleiotropic regulators have an effect on Act production in *S. coelicolor*. For more extensive overviews of the control of antibiotic production, we refer to reviews elsewhere [16, 79, 151]. Several general themes related to the control of *act* production are highly relevant for approaches to wake up sleeping antibiotics, and are worked out in more detail in the following sections of this review.

The *act* gene cluster consists of around 20 genes, organized in several transcription units [82]. ActII-ORF4 is the cluster-situated and pathway-specific regulator of the *act* gene cluster that binds to target sequences of the *act* promoters, with an N-terminal helix-turn-helix DNA binding domain and a C-terminal transcriptional activation domain [62]. ActII-ORF4 is a member of a family of pathway-specific activator proteins termed *Streptomyces* antibiotic regulatory proteins or SARPs [160]. SARP regulators are typically expressed in a growth phase-dependent manner and at a high level [16], and there appears to be little or no control downstream. This is exemplified by promoter probing experiments using *redD*—the pathway-specific activator gene for the *red* cluster—as a reporter; which demonstrated that both timing and level of expression of the *red* cluster is directly proportional to the expression of RedD, even in early vegetative mycelia or in aerial hyphae, where the cluster is normally not expressed [154].

Many pleiotropic regulators characterized so far are required only under specific environmental conditions [17],

and several of these control *act* gene expression. DasR is a GntR-family regulator that controls among others amino sugar metabolism and transport and the chitinolytic system [29, 30, 124, 140]. DasR is a highly pleiotropic regulator, and in a recent environmental study, microarray data on the *dasR* null mutant in soil-grown cultures in the presence of chitin revealed some 700 genes that were differentially expressed [98]. DasR connects the control of primary and secondary metabolism by directly controlling the transcription of *actII-ORF4*, the pathway-specific activator gene for actinorhodin biosynthesis (Fig. 1), and *redZ*, a response regulator required for undecylprodigiosin production. The DasR regulon and its use as target for global approaches to induce antibiotic production is discussed in detail below.

AtrA is a TetR-family protein that is required for the transcription of *actII-ORF4* [148], and in turn responds to the level of phosphate as it is repressed by the PhoRP system [130]. Further complexity is offered by Rok7B7, a member of the ROK family of proteins, which are

Fig. 1 Pleiotropic and nutrient-mediated control of actinorhodin production in *S. coelicolor*. *N*-acetylglucosamine (GlcNAc) enters the cell and is subsequently phosphorylated via the GlcNAc-specific phosphoenolpyruvate-dependent phosphotransferase system (PTS), composed of intracellular PTS proteins EI, HPr, and EIIB, and the GlcNAc-specific components EIIB (NagE2) and EIIC (NagF). Phosphoenolpyruvate (PEP) is the phosphodonor. *N*-acetylglucosamine-6-phosphate (GlcNAc-6P) is then deacetylated by GlcN-6P deacetylase NagA to glucosamine-6-phosphate (GlcN-6P), the effector molecule that inhibits DasR DNA-binding. This results in

derepression of *actII-ORF4*, the pathway-specific transcriptional activator gene for the actinorhodin biosynthetic gene cluster. This represents a complete signaling cascade from extracellular nutrients to the activation of actinorhodin production. The global regulators AtrA and Rok7B7 have opposite activities to DasR, with AtrA and Rok7B7 both activating actinorhodin production, and at least AtrA also activating GlcNAc transport, thereby antagonizing DasR. Rok7B7 is likely activated by a xylose-derived C5 sugar transported via the ABC transporter XylFGH. For details and references, see the text. The effect of GlcNAc on antibiotic production is shown in Fig. 2

predominantly sugar regulatory proteins and sugar kinases, including glucose kinase [146]. Rok7B7 pleiotropically affects primary and secondary metabolism, and is required for actinorhodin production [139]. Introduction of an ortholog of *rok7B7* called *rep*, obtained from a metagenomic library, appeared to be an effective way of activating antibiotic production in *S. coelicolor* [90]. Recent evidence suggests that Rok7B7 may be activated by a derivative of the C5 sugar xylose [139]. The activity of DasR, Rok7B7, and perhaps also AtrA is subject to nutrient control at the posttranslational level, and the metabolic status of the cell will therefore largely determine their contributions to the control of antibiotic production.

Other pleiotropic antibiotic regulators involved in the control of *actIII-ORF4* are AfsR and PhoP. AfsR contains an N-terminal SARP domain and is conditionally required for Act and Red production [43]. AfsR binds to the promoter of the downstream located *afsS* (also called *afsR2*) and activates its transcription [75]. While the precise function of *afsS* is unclear, it activates antibiotic production in many streptomycetes, and is therefore an attractive target for the activation of antibiotic production. PhoP, which represses actinorhodin production in response to phosphate, probably acts indirectly, and perhaps by repressing *afsS*. The role of PhoP in the control of antibiotic production is discussed in more detail in the next section.

Interestingly, deletion of the gene for *Streptomyces* integration host factor (sIHF) also effects enhanced actinorhodin production [166]. IHF assists in cell processes that require higher-order protein complexes, e.g., DNA replication, transcriptional regulation, and site-specific recombination [44]. Again, the effect of sIHF on antibiotic production is most likely direct, as EMSAs showed direct binding to the *redD* promoter region [166]. Finally, the two-component system DraR-K controls antibiotic biosynthesis in *S. coelicolor* in response to high concentrations of nitrogen [168]. Phospho-DraR enhances the production of Act but represses yellow pigmented type I polyketide (yCPK) biosynthesis via direct control of the pathway-specific activator genes *actIII-ORF4* and *cpkO*, respectively, while repression of Red biosynthesis is indirect [168]. Besides the selection of regulatory proteins mentioned above, a surprisingly large number of other genes affect the expression of *actIII-ORF4* [79, 151]. This highlights the amazing regulatory complexity for a gene cluster that apparently specifies a compound with weak antibiotic activity, suggesting that *actIII-ORF4* and/or the *act* cluster may have a more important physiological role than currently anticipated.

Genetic control in response to carbon, nitrogen, and phosphorous

Most secondary metabolites are produced in a growth phase-dependent manner, typically during the onset of

development, corresponding to transition phase and early stationary phase in submerged cultures. Nutrient composition and concentration within media not only affects growth rate but also influences complex changes in global gene regulation, reflecting the range of conditions that trigger the production of different antimicrobials in nature [16, 128, 151].

Carbon sources have a major impact on the expression of biosynthetic genes and morphological development of microorganisms. Carbon catabolite repression (CCR) occurs when media contains mixtures of rapidly and slowly used carbon sources and is a regulatory mechanism commonly observed in bacteria [22, 45, 145]. After exhausting the preferred carbon source, bacteria turn to the “second-best” carbon source, and this often correlates temporally with the onset of antibiotic production, which is associated with growth cessation [36]. Glucose is a preferred carbon source for many actinomycetes and effects global repression of antibiotic production [37, 118], which is why in industrial fermentations, polysaccharides (e.g., starch), oligosaccharides (e.g., lactose) and oils (e.g., soybean oil, methyloleate) are commonly used.

The central protein that controls CCR in streptomycetes is glucose kinase (Glk), with deletion of the gene for glucose kinase resulting in global derepression of carbon utilization [5, 6]. Glk expression is constitutive, and its activation takes place posttranslationally in glucose-grown cultures, but not when cultures are grown on non-repressing sugars [149]. This suggests that interfering with the activation of the CCR activity of Glk, while leaving glycolysis unchanged, should enable antibiotic production in glucose-grown cultures, which would be a major advantage for industrial fermentations. To address this, a comprehensive quantitative proteome analysis was performed on cultures of *S. coelicolor* and its *glkA* mutant grown in minimal media with mannitol or fructose and with or without additional glucose, which revealed the response of nearly all enzymes in central metabolism and most antibiotic-related pathways. This surprisingly showed that while CCR and inducer exclusion of the majority of the primary and secondary metabolic pathways was mediated in a Glk-dependent manner (as expected), glucose repression of the biosynthesis of the γ -butyrolactone ScbI and the responsive *cpk* gene cluster for the cryptic polyketide Cpk is independent of Glk [47]. Other cryptic pathways could perhaps also be controlled in an entirely different way, providing a possible new lead for the activation of poorly expressed antibiotics.

High concentrations of nitrogen sources such as ammonium or amino acids also suppress the biosynthesis of secondary metabolites [1, 86]. Complex fermentation media therefore include proteins as nitrogen source and defined media slowly assimilated amino acids, so as to

ensure optimal antibiotic production. For example, streptomycin production by *Streptomyces griseus* is favored by growth in both soybean meal and proline in combination with low concentrations of additional ammonium salts [39, 162]. Production of aminoglycoside antibiotics was also repressed by ammonium salts, whereas nitrate and certain amino acids stimulated their production [132].

Biosynthesis of antibiotics and other secondary metabolites is transcriptionally repressed by easily utilized phosphate sources [85]. The depletion of phosphate in the environment triggers the biosynthesis of secondary metabolites but represses growth [86]. Generally, phosphate concentrations above 0.5 mM stimulate growth at the expense of secondary metabolism, while, conversely, below this threshold the production of secondary metabolites is favored, including antibiotic production [156]. This activation of antibiotic production is among others governed via autoregulatory signals [54, 101, 164]. A major system for the global control of gene expression in response to the phosphate concentration is the two-component regulatory system PhoRP [136]. PhoRP is widespread in prokaryotes and is involved in the control of antibiotic production in among others *S. coelicolor* and *Streptomyces lividans* (Act, Red; [129, 135]), *S. griseus* (candicidin; [87]), *S. natalensis* (pimaricin; [95]) and in *Streptomyces rimosus* (oxytetracycline; [92]), although phosphate-mediated repression is a general phenomenon [88].

Sensory histidine kinase PhoR is prevented from phosphorylating its cognate response regulator PhoP via its interaction with the high-affinity phosphate transport system Pst, which in turn is activated by PhoR. Thus, only little phosphate transporter is produced when sufficient phosphate is available. However, during phosphate limitation, PhoR is released and phosphorylates PhoP, resulting in enhanced phosphate transport and utilization [85, 136]. Recent global analysis of PhoP binding sites by immunoprecipitated genomic DNA hybridized to DNA microarrays (ChIP-chip) showed that besides controlling the phosphate regulon, PhoP also transiently shuts down central metabolic pathways [3]. PhoP directly controls the pathway-specific regulatory gene *cdaR* for Cda production in *S. coelicolor*, but control of actinorhodin and undecylprodigiosin production is most likely indirect, as there are no obvious PhoP-binding sites in the promoter regions of the pathway-specific regulatory genes *actII-ORF4* and *redD/redZ*, respectively, and PhoP failed to bind to the promoters [85]. However, PhoP may affect these antibiotics indirectly via the control of *afsS* [130].

In addition, PhoP plays a major role in the cross-talk between N- and P-metabolism, via the repression of *glnR*, for the global nitrogen regulator GlnR [89, 126]. Therefore, PhoP takes up a central role in the junction between

primary and secondary metabolism, and targeting this system is an attractive approach to pleiotropically affect antibiotic production.

Genetic tools for the activation of antibiotic production

Enhanced expression of SARP regulators is an effective yet strain-specific approach for the overexpression of the gene clusters they control. However, the associated gene clusters are often “household” antibiotics, i.e., they are expressed under most growth conditions, typically during the transition from late exponential to stationary growth [16]. This suggests that most antibiotics specified by SARP-controlled gene clusters will have been identified in HTS screening efforts by BigPharma.

Recently, a new class of regulatory genes was identified, which encode proteins with similarity to LAL (Large ATP binding regulators of the LuxR family) proteins [72]. Constitutive expression of a pathway-specific LAL regulator as CSR for a giant (150 kb) type-I modular polyketide synthase (PKS) gene cluster in *Streptomyces ambofaciens*, resulted in the production of a number of novel 51-membered glycosylated macrolides, named stambomycins A–D [72]. Since genome sequencing identified LAL regulators that are associated with several yet unidentified gene clusters, constitutive expression of such CSRs represents a promising new approach for natural product discovery.

The enhanced expression of *afsS* appears to be an effective and generally applicable way of activating antibiotic production. Its enhanced expression stimulates antibiotic production in among others *S. coelicolor* [91], *S. lividans* [157], *S. avermitilis* [74], and *S. noursei* [131]. The overexpression of AfsR also increased antibiotic production, for example in *S. coelicolor* [43], *S. peucetius* [115], and *S. venezuelae* [81], which is perhaps mediated via activation of *afsS* [75]. The effect of the *afsS* orthologue *ssmA* on nistatin production by *S. noursei* suggests that perhaps *afsRS* act in a carbon source-dependent manner [131].

Ribosome engineering

An effective and very promising way to activate antibiotic production is manipulation of the strains via so-called “ribosome-engineering”, developed by Kozo Ochi and colleagues (recently reviewed in [106, 108]). Ribosome engineering is a method that uses sub-lethal concentrations of antibiotics that target either the ribosome itself or RNA polymerase (RNAP). Drug-resistant mutants enforced by rifampicin have mutations in *rpoB* (for the β -subunit of the RNAP), while those induced by streptomycin carry mutations in *rpsL* for ribosomal protein S12 or also in *rsmG* for

a 16S rRNA methyltransferase, which gives lower resistance. Combinations of mutations in *rpoB*, *rpsL*, or *rsmG* typically leads to further enhancement of antibiotic production [106, 142, 144]. The ribosome engineering technology proved to be successful in the activation of Act production in *S. coelicolor* and *S. lividans*, but was also successful in triggering antibiotic production in less well-studied actinomycetes, such as the production for novel piperidamycins by *S. mauvecolor* triggered by a number of different *rpoB* or *rpsL* mutations [56]. The wide application is further demonstrated by the fact that production of the normally silent amino sugar antibiotic 3,3'-neotrehalos-diamine (NTD) by the firmicute *Bacillus subtilis* was activated by an *rpoB* mutation [61]. Inducing resistance to several other antibiotics such as gentamicin, erythromycin, and capreomycin also activated antibiotic production, and resistance to these structurally diverse antibiotics typically relates to deletion or expression of an rRNA methyltransferase [63, 80, 134]. A major advantage from the application point of view is that introducing antibiotic resistant mutations can be done by a straightforward selection procedure, rather than by introducing specific mutations, and the technology therefore finds wide application [2, 13, 106, 120, 155]. For further details, we refer to the review by Ochi and colleagues elsewhere in this issue.

Ecological considerations and co-cultivation

If we are to activate silent antibiotic gene clusters, then understanding of their biological role is of major importance. Streptomycetes grow as a branched multicellular network of hyphae—the vegetative or substrate mycelium—and reproduce through spores that are formed by a specialized aerial mycelium. The onset of development is triggered by stress conditions such as drought or famine. A proportion of the vegetative mycelium lyses following a process of programmed cell death [83], which releases nutrients that presumably form the building blocks for the sporulation process. For a detailed description of the control of morphological differentiation of streptomycetes, we refer to excellent reviews elsewhere [27, 41, 52]. It is likely that the release of nutrients in an otherwise depleted environment attracts competing microbes, and it is logical to perceive the production of antibiotics as a defense mechanism. Indeed, many antibiotics are produced at a time correlating to the onset of development [16, 17, 151].

A major issue connected to existing strain collections is that they are just that, collections, i.e., the microorganisms have been taken out of their ecological context, and the strains are typically screened individually. Inevitably, in nature, many antibiotics will only be produced after receipt of specific signals, such as from the environment (stress) or

from surrounding microbes (symbionts or competitors). Novel molecular ecological methods should aid us in understanding and identifying the triggers that activate the production of antibiotics in nature, which explains the rapidly growing interest in soil and marine ecology related to the production of antibiotics in the natural habitat. The original view that antibiotics are purely antagonistic, acting in nature as they do in the clinic, has recently been questioned [77, 121, 127]. First, the concentrations of antibiotics in the soil are argued to be too low to be efficacious. Second, sub-inhibitory concentrations of antibiotics induce novel phenotypic and genetic responses in exposed organisms, including increased biofilm formation and expression of virulence genes. Thus antibiotics may also act as “collective regulators of the homeostasis of microbial communities”, in others words act as signals or cues rather than weapons [77, 121]. Antibiotics acting as signals enable symbiotic relationships between different organisms, each benefiting from either nutrition or protection. The way microbes influence each other has recently been beautifully displayed by Pieter Dorrestein and colleagues, who used imaging mass spectrometry to visualize secondary metabolites and signaling molecules produced by microbes grown in close proximity [68, 158, 167]. The power of this technology is that—in particular with increasing resolution—it may directly identify new chemical elicitors that activate antibiotic production by actinomycetes.

Co-cultivation of different bacterial species was applied successfully to activate the expression of novel antibiotics. The novel antimicrobial alchivemycin A was produced via the co-cultivation of *Tsukamurella pulmonis* TP-B0596, a mycolic acid-containing bacterium, together with *Streptomyces endus* S-522. It was proposed that mycolic acid located in the outer cell layer of *Tsukamurella* induced secondary metabolism in *Streptomyces* [113]. A competition-based adaptive assay has recently been developed, encouraging the evolution of an organism to produce antimicrobials via serial co-cultivations with a target pathogenic bacterium such as MRSA. Results revealed the activation of the anti-staphylococcal agent holomycin when *Streptomyces clavuligerus* was co-cultured with MRSA for consecutive passages until significant bioactivity was elicited [26]. While perhaps not feasible in larger screening efforts, such pair-wise interactions may identify important cues and triggers for poorly expressed antibiotics in actinomycetes, which may find wider application.

Chemical elicitors of antibiotic production

With the promise of finding novel antibiotics, the exploration of elicitors able to activate the expression of silent antibiotic biosynthetic gene clusters has begun, aimed at

optimal exploitation of the seemingly enormous potential. This section highlights some of the recent advances in this promising line of research.

N-acetylglucosamine and the DasR regulon

A signaling cascade from an extracellular nutrient to the activation of antibiotic production was elucidated in *S. coelicolor*, which is based on the derepression of the regulon of the GntR-family regulator DasR. Higher concentrations of the cell-wall component *N*-acetylglucosamine (GlcNAc; 5–10 mM) trigger development and antibiotic production under poor growth conditions (“famine”), while they activate development under rich (“feast”) conditions (Fig. 2a; [125]). The final receptor of the GlcNAc-derived signal is DasR. GlcNAc is imported via the PEP-dependent phosphotransferase system PTS [102, 103], and subsequently metabolized to glucosamine-6-phosphate (GlcN-6P), an important starter molecule for cell-wall biosynthesis (Fig. 1). GlcN-6P is a ligand for DasR by binding to its effector binding site and thereby reducing the protein’s affinity for DNA [124]. This is not unexpected, as GlcN-6P stands at the crossroads of (GlcNAc)_n degradation, GlcNAc transport, and intracellular metabolism, glycolysis, nitrogen and lipid metabolism, as well as peptidoglycan synthesis [4, 84], and many genes of these pathways are subject to control by DasR. A complete signaling pathway was established from import of a signal (GlcNAc; first step) to the activation of pathway-specific regulatory genes (*actII-ORF4*, *redZ*; final step), see Fig. 1. Interestingly, AtrA appears to counteract DasR, by having opposite actions on the start and end of this signaling pathway. While DasR represses transcription of the genes for the GlcNAc-specific transporter NagE2 (signal import) and for ActII-ORF4 (antibiotic activation), both of these genes are transcriptionally activated by AtrA [103].

The transcription of all known chromosomally encoded antibiotic biosynthetic clusters of *S. coelicolor* (*act*, *cda*, *red*, and the “cryptic” *cpk* cluster) is enhanced in *dasR* mutants [125], while DasR also controls siderophore production [32]. Therefore, manipulating the activity of DasR should potentially allow triggering the expression of antibiotics. Indeed, growth of *S. coelicolor* on minimal media agar plates containing only GlcNAc as the carbon source accelerated development and enhanced antibiotic production, and this was also observed for a number of other actinomycetes [125, 152]. An example is presented in Fig. 2c, which shows the effect of GlcNAc on antibiotic production by six streptomycetes. Interestingly, the *cpk* cluster for the cryptic type I polyketide synthase Cpk is also induced by the addition of *N*-acetylglucosamine [125]. This provides one example of novel approaches that may be employed to boost the potential of novel screening

procedures. Alternatively, creating mutants in the *nag* metabolic genes disturbed GlcNAc metabolism in such a way that metabolic intermediates accumulated intracellularly, resulting in increased antibiotic production [141].

It should be noted, however, that GlcNAc and glutamate are also important carbon and nitrogen sources for streptomycetes, and glutamate is preferred over glucose by *S. coelicolor* [102, 150]. The fact that GlcNAc and its direct metabolic derivatives promote growth may explain why the compound suppresses antibiotic production in a number of actinomycetes, even though it activates the production in others.

Chemical elicitors that modulate fatty acid biosynthesis

Besides GlcNAc, other molecules that result from macromolecule recycling should also be considered as elicitors, such as nucleotides from DNA and RNA, oligopeptides and amino acids from proteins, sugars from polysaccharides (including extracellular matrix EPS and LPS) and fatty acids from lipids. Interestingly, a recent screen by Justin Nodwell and colleagues of a chemical library of around 30,000 small molecules for compounds that can act as elicitors of antibiotic production, revealed a family of molecules that act by modulating fatty acid biosynthesis, referred to as antibiotic remodeling compounds (ARCs; [33]), which show similarity to the structure of the furan-like antibiotic triclosan (Fig. 3). Of the ARCs, ARC2 was the most active one. It acts via inhibition of the enoyl-acyl carrier protein reductase FabI, which is a key enzyme of type II fatty acid biosynthesis. Secondary metabolism and fatty acid biosynthesis compete for the common substrate acetyl-CoA, and ARC2 may act via the partial inhibition of FabI, thus allowing a preferential flow of acetyl-CoA to antibiotic production [33, 107].

However, besides interfering with fatty acid metabolism, triclosan is also known to affect quorum sensing and auto-induction mechanisms [38], which mediate cell–cell communication. Quorum sensing-regulated genes were among the most strongly downregulated genes in triclosan-treated *Pseudomonas aeruginosa* cells [28]. In streptomycetes, quorum sensing-like communication is mediated by γ -butyrolactones, and these play a role in the control of antibiotic production (see next section), and triclosan might also act by interfering with this system.

Extracellular signaling molecules

Microbial, hormone-like, small diffusible molecules known as γ -butyrolactones play a role in the communication between actinomycetes in the soil, controlling development and antibiotic production (recently reviewed in [57, 133, 161]). The best known example is A-factor (Fig. 3), a

Fig. 2 Medium-dependent activation of antibiotic production by elicitors. Increasing concentrations of GlcNAc (**a**) or sodium butyrate (NaBu; **b**) repress antibiotic production and development under rich growth conditions (R5 agar plates; “feast”) and activate developmental processes in cultures grown under poor conditions (MM agar plates; “famine”). GlcNAc acts by interfering with the activity of DasR, while NaBu is known to target histone deacetylase (HDAC). The blue pigment is the polyketide antibiotic actinorhodin, spores are

grey-pigmented. **c** Effect of GlcNAc on antibiotic production by six selected streptomycetes. The strains were grown on minimal medium agar plates with mannitol (1 % w/v) or *N*-acetylglucosamine (25 mM) as the sole carbon source. *Bacillus subtilis* was used as indicator strain. Halos correspond to antibiotics produced by the streptomycetes. Note that *N*-acetylglucosamine inhibits antibiotic production by *S. roseosporus*. Fig. 2a, c based on [125], Fig. 2b adapted with permission from [96]

Fig. 3 Chemical elicitors of antibiotic production. Chemical structures are presented for known elicitors of antibiotic production and related molecules. For details, we refer to the relevant sections on chemical elicitors in the text

diffusible autoregulatory signaling molecule that controls development and streptomycin production in *S. griseus* at very low concentrations [55, 110]. The key enzyme that mediates the biosynthesis of A-factor is the product of the *afsA* gene product [65]. When A-factor reaches a critical level it binds to the TetR-family regulator ArpA, which consequently dissociates from the *adpA* promoter, thereby alleviating its repression. In turn, AdpA then globally *trans*-activates developmental and antibiotic genes [110]. Antimicrobial regulatory systems that involve

γ -butyrolactones have been discovered in many *Streptomyces* species, controlling among others the production of Lankacidin and Lankamycin in *Streptomyces rochei* [165], virginiamycin production in *Streptomyces virginiae* [66], showdomycin and minimycin in *Streptomyces lavendulae* [69], auricin production by *Streptomyces aureofaciens* [104], and the biosynthesis of the type I modular polyketide Cpk in *S. coelicolor* A3(2) [34]. The activation of many other antibiotics is likely also mediated through γ -butyrolactones. A second *afsA*-like gene, *mmfL*, occurs in

S. coelicolor, which is involved in the biosynthesis of methylenomycin furans (MMFs; Fig. 3), controlling a signaling pathway involved in regulation of methylenomycin biosynthesis. Like GBLs, MMFs are synthesized via a butenolide intermediate [31].

Conceivably, γ -butyrolactones may be applied for drug discovery, as shown by surprising antibiotic stimulation in *Streptomyces natalensis* by the addition of A-factor from *S. griseus*. *S. natalensis* produces the autoinducer molecule PI factor (2,3-diamino-2,3-bis (hydroxymethyl)-1,4-butane-diol; Fig. 3), which is required for the activation of pimarin production in this organism [123]. Pimaricin is a 26-membered macrolide tetraene with antifungal activity [7]. Mutants that fail to produce PI factor can not only be restored to produce pimarin by the addition of PI factor itself, but also by A-factor. While PI factor has a stronger stimulatory effect than A-factor, the cross-complementarity is remarkable. Another example of overlapping signaling routes was found for A-factor and the signaling protein Factor C [19] from *Streptomyces flavofungini* (originally regarded as a variant of *S. griseus*), although this time it is the lack of A-factor that is complemented. Factor C fully restored normal development and streptomycin production to an A-factor nonproducing strain (AFN) of *S. griseus*, even though *S. griseus* does not produce Factor C itself [20]. Factor C restored wild-type levels of A-factor production to the AFN mutant via a yet-unknown mechanism [18], and elucidation of this mechanism should shed new light on the way A-factor production is induced.

Little is yet known about possible application of these signaling molecules as global elicitors of antibiotic production, but considering their activity at very low concentrations this is an interesting approach to follow. Approaches to apply GBLs and MMLs for the activation of antibiotic production were recently proposed by Corre and coworkers [133], and the effect of the furan-like triclosan and the related ARC molecules (previous section) is further support for this conceptual idea.

Rare earth elements

Rare earth elements (REEs) have recently been implicated as activators of poorly expressed secondary metabolites [106, 108]. Scandium and/or lanthanum enhanced the production of actinomycin, actinorhodin, and streptomycin by two- to as much as 25-fold at 10–100 μ M concentrations in *Streptomyces antibioticus*, *S. coelicolor*, and *S. griseus*, respectively. Moreover, scandium also activated actinorhodin in *S. lividans* [67, 143] and amylase and bacilysin production in *B. subtilis* [60]. REEs are widely distributed and microorganisms respond to their presence in their environment. Addition of REEs, and in particular scandium [106], during screening, may be a useful addition

to the array of tools researchers have at their disposal to elicit the production of antibiotics.

HDAC inhibitors

Another recent addition to the arsenal of chemical elicitors are inhibitors of histone deacetylases or HDACs. Molecules that affect histone acetylation, and thereby change chromatin structure, were shown to activate biosynthetic clusters for natural products in fungi [21, 138]. HDACs antagonize the acetylation of histones in eukaryotes, leading to alterations in chromosome structure and thus affecting gene expression [137]. HDAC proteins are widespread and many are found in bacteria [76], with three HDAC-like genes identified in *S. coelicolor* [96]. Analysis of the effect of sodium-butyrate, a well-known HDAC inhibitor (Fig. 3), on antibiotic production by *S. coelicolor* showed a major effect on actinorhodin production [96]. Surprisingly, the response of *S. coelicolor* displayed a similar context-dependence as previously observed for *N*-acetylglucosamine [125], namely enhanced production of actinorhodin on minimal media (“famine”) and repression under rich (“feast”) growth conditions (Fig. 2b; [96]). Whether there is a correlation between the mechanisms by which *N*-acetylglucosamine and sodium-butyrate enhance antibiotic production awaits further investigation.

Genome mining

PKS and NRPS gene clusters can be readily identified using bioinformatics, and the natural products they specify can be predicted based on protein domain structures [9, 73]. In recent years, there has been a great expansion in bioinformatics programs enabling the identification of genes involved in secondary metabolite production. This includes ANTibiotics and Secondary Metabolite Analysis SHell (antiSMASH) [93] and Secondary Metabolite Unknown Regions Finder (SMURF), which facilitate the automated detection of secondary metabolite biosynthesis gene clusters in genome sequence assemblies. Other software packages, such as CLUster SEquence ANalyzer (CLUSEAN), ClustScan, Structure Based Sequence Analysis of Polyketide Synthases (SBSPKS), NRPSPredictor, and Natural Product searcher (NP.searcher), enable the identification of secondary metabolite backbone biosynthesis genes [40]. Other packages include the NORINE database for nonribosomal peptides [23] and BAGEL, which is specific for the identification of biosynthetic clusters for bacteriocins and lantibiotics [35].

The rapid decline in cost made genome sequencing a feasible strategy for identification of gene clusters. Helped by the new software tools that have become available,

thousands of gene clusters have now been identified, and many more have undoubtedly been elucidated outside the public domain. However, how can we efficiently deal with this wealth of information? Expressing them one by one is like looking for the proverbial needle in a haystack, so how can we identify those clusters that may qualify as producing novel compounds? Following the initial excitement of the massive amount of new cluster data, we should not just focus on identifying homologs of known biosynthetic gene clusters. Instead, we should make use of computational techniques to intelligently sieve through the data for interesting new biochemistry. For example, all gene clusters may be subdivided into families using an evolutionary distance metric (Cimermancic, Medema, Fischbach et al., unpublished data). This allows one to focus on families without gene clusters encoding the biosynthesis of known compounds. Alternatively, one could focus on families that contain gene clusters with entirely novel combinations of homologs of well-known enzymes. Such gene clusters are likely associated with specific types of regulatory genes and/or regulatory elements, as well as genes for modifying enzymes and transporters. Genomic, transcriptomic, and/or proteomic data may be used as further support, e.g., to select those clusters that appear poorly expressed under routine growth conditions. Here we look at *cis*-acting elements and specific regulatory genes that may act as so-called “molecular beacons” [11], which may point scientists in the right direction in their search for novel antibiotic biosynthetic gene clusters.

Regulatory elements as beacons

In terms of scanning the genomes of yet un(der)explored streptomycetes, following the distribution of regulatory elements for global antibiotic regulators may be a useful strategy. As an example, scanning the *S. coelicolor* genome using the PREDetector algorithm [49] revealed some 200 sequences that conformed to the consensus binding site for DasR (*dre*, for DasR responsive element), namely the palindromic 16-bp consensus sequence A(G/C)TGGTCTA GACCA(G/C)T. The DasR regulatory network is well conserved in streptomycetes, with around 75 % of the DasR-binding (*dre*) sites predicted in *S. coelicolor* also found upstream of the orthologous genes in *S. avermitilis* (Rigali, Titgemeyer and van Wezel, unpublished data and [153]). Scanning genome sequences in the databases suggested that DasR may control the biosynthesis of novel antibiotics as well as important clinical drugs, including clavulanic acid, chloramphenicol, daptomycin, and teicoplanin.

A similar approach could be followed by analyzing the distribution of the regulatory element of AtrA, which among others controls actinorhodin production in

S. coelicolor [148]. AtrA recognizes the consensus sequence cGGAA(T/C)(G/C)NNN(C/G)(A/G)TTCCg (are, for AtrA-responsive element) and likely qualifies as a global regulator (K.J. McDowall, pers. comm.). AtrA occurs in all streptomycetes, its DNA binding domain is extremely well conserved (>90 % aa identity), and an AtrA orthologue activates streptomycin production in *S. griseus* [50]. Following a similar approach to the DasR regulatory network should reveal how the AtrA network associates with (novel) secondary metabolite gene clusters. The same is true for other regulatory networks.

Regulatory genes as beacons

mbtH-family genes and NRPS

The gene *mbtH* was identified in *Mycobacterium tuberculosis* within the NRPS gene cluster for mycobactin, a peptide siderophore. The *mbtH*-like genes are widespread in *Streptomyces* genomes, and some of the gene products stimulate adenylation reactions by tightly binding to NRPS proteins containing adenylation (A) domains. Their expression may be important for the efficient production of native and recombinant secondary metabolites produced using NRPS enzymes [11]. As an example, *vbsG*, an *mbtH* homolog in *Rhizobium leguminosarum*, is required for the production of the cyclic, trihydroxamate siderophore vicibactin [24]. Thus, *mbtH* homologs can be useful for identification of specific types of NRPS gene clusters [11].

mmvB-family regulatory genes

The *mmvB*-like genes are also candidates as beacons for antibiotic biosynthetic gene clusters. *mmvB* itself is a transcriptional regulatory gene involved in the biosynthesis of methylenomycin in *S. coelicolor* [105]. The crystal structure of the MmyB-family regulator MltR from *Chloroflexus aurantiacus* was resolved; the proteins consist of an Xre-type N-terminal DNA-binding domain and a C-terminal ligand-binding module that is related to the Per-Arnt-Sim (PAS) domain, and these regulators most likely bind complex fatty acid molecules as ligands that activate their DNA binding activity [163]. Many *mmvB*-family regulatory genes lie divergently transcribed from, and share the promoter region with, genes related to antibiotic production. There are eight in total in *S. coelicolor*, including *mmvB* itself, which controls Mmy biosynthesis and SCO6925, which lies next to a lantibiotic biosynthetic cluster. The other genes are adjacent to a gene for an NAD(P)H-dependent short- or medium-chain dehydrogenases/reductase (SDR or MDR), a diverse family with alcohol dehydrogenase as the best known example [64]. This suggestive linkage is conserved in actinomycetes,

Fig. 4 Approaches to activate antibiotic production. Summary of methods applied to increase or induce the production of secondary metabolites. From *left to right*, technologies are presented with increasing applicability at higher throughput, from strain-specific

(directed mutants, expression of activators) to HT screening using elicitors. Genome mining approaches range from single genome sequencing and annotation (*left*) to global genome comparison (*right*). For details on the technologies, see the text

suggesting that the genetic association with antibiotic-related genes appears to be widespread.

The *mmvB*-family gene SCO4944 is conserved in streptomycetes and other actinomycetes, and may therefore be seen as the main member of the family in actinomycetes. Phylogenetic evidence suggests that SCO4944 may control SCO4945, a gene for a mycothiol-dependent formaldehyde dehydrogenase. Surprisingly, the orthologs in *S. griseus*, SGR_6891 and SGR_6892, respectively, are separated by one gene from *afsA* (SGR_6889) for A-factor synthase, and their transcription is induced by A-factor immediately after its addition to liquid-grown cultures [48], suggesting that both genes are part of A-factor regulatory cascade. Suggestively, MmyB binds furans as ligands, which are structurally similar to A-factor.

Thus, *mmvB* homologs may form a very useful tool as genetic beacon for the identification of antibiotic-related genes in actinomycete genomes, and that searching for large gene clusters with suggestive genes such as modifying enzymes and transporters could be a fruitful strategy for finding new candidate antibiotic biosynthetic clusters.

Final considerations

With next-generation sequencing technologies and the increasing understanding of antibiotic regulation, new strategies for “awakening” poorly expressed antibiotics are becoming available. A combination of different regulatory approaches should be considered for activating antibiotic production, such as the application of elicitor molecules or transcription stimulation, to enhance the expression of novel biosynthetic gene clusters. Important approaches to explore also lie in the direction of culture conditions. The different methods range from strain-specific to globally applicable (Fig. 4). One obvious problem with routine screening methods is the absence of the natural competitors and symbionts that are found in the natural habitat. Co-cultivation methods or chemical mimicking of inter-species

communication are promising new approaches in the search for novel antibiotics. One aspect that has obtained surprisingly little attention is that while most scientists search for novel antibiotics, the problem lies not so much in the lack of antibiotics, but in the widespread resistance that limits their application. The success story of clavulanic acid as inhibitor of β -lactamases [114, 122] perfectly illustrates the potential of such approaches. Therefore, targeting antibiotic resistance should offer a very attractive alternative to antibiotic discovery. We anticipate that similar considerations as those described above for antibiotics will also be applicable to the activation of natural products involved in counteracting antibiotic resistance mechanisms.

Acknowledgments We are grateful to Young Choi for drawing chemical structures, to Geneviève Girard for comments on the manuscript, and to Kenneth McDowall, Marnix Medema and Michael Fischbach for sharing unpublished data. The work was supported by a CSC PhD fellowship from the Chinese government to HZ and by grant 10467 from the Netherlands Technology Foundation STW to GPvW.

References

- Aharonowitz Y (1980) Nitrogen metabolite regulation of antibiotic biosynthesis. *Annu Rev Microbiol* 34:209–233
- Alexander DC, Rock J, He X, Brian P, Miao V, Baltz RH (2010) Development of a genetic system for combinatorial biosynthesis of lipopeptides in *Streptomyces fradiae* and heterologous expression of the A54145 biosynthesis gene cluster. *Appl Environ Microbiol* 76:6877–6887
- Allenby NE, Laing E, Bucca G, Kierzek AM, Smith CP (2012) Diverse control of metabolism and other cellular processes in *Streptomyces coelicolor* by the PhoP transcription factor: genome-wide identification of in vivo targets. *Nucleic acids Res* 40:9543–9556
- Altermann E, Klaenhammer TR (2005) PathwayVoyager: pathway mapping using the Kyoto Encyclopedia of Genes and Genomes (KEGG) database. *BMC genomics* 6:60
- Angell S, Lewis CG, Buttner MJ, Bibb MJ (1994) Glucose repression in *Streptomyces coelicolor* A3(2): a likely regulatory role for glucose kinase. *Mol Gen Genet* 244:135–143

6. Angell S, Schwarz E, Bibb MJ (1992) The glucose kinase gene of *Streptomyces coelicolor* A3(2): its nucleotide sequence, transcriptional analysis and role in glucose repression. *Mol Microbiol* 6:2833–2844
7. Aparicio JF, Colina AJ, Ceballos E, Martin JF (1999) The biosynthetic gene cluster for the 26-membered ring polyene macrolide pimarin. A new polyketide synthase organization encoded by two subclusters separated by functionalization genes. *J Biol Chem* 274:10133–10139
8. Arias CA, Murray BE (2009) Antibiotic-resistant bugs in the 21st century—a clinical super-challenge. *N Engl J Med* 360:439–443
9. Bachmann BO, Ravel J (2009) Chapter 8. Methods for in silico prediction of microbial polyketide and nonribosomal peptide biosynthetic pathways from DNA sequence data. *Methods Enzymol* 458:181–217
10. Baltz RH (2007) Antimicrobials from actinomycetes: back to the future. *Microbe* 2:125–131
11. Baltz RH (2011) Function of MbtH homologs in nonribosomal peptide biosynthesis and applications in secondary metabolite discovery. *J Ind Microbiol Biotechnol* 38:1747–1760
12. Baltz RH (2008) Renaissance in antibacterial discovery from actinomycetes. *Current Opin Pharmacol* 8:557–563
13. Beltrametti F, Rossi R, Selva E, Marinelli F (2006) Antibiotic production improvement in the rare actinomycete *Planobispora rosea* by selection of mutants resistant to the aminoglycosides streptomycin and gentamycin and to rifamycin. *J Ind Microbiol Biotechnol* 33:283–288
14. Bentley SD, Chater KF, Cerdano-Tarraga AM, Challis GL, Thomson NR, James KD, Harris DE, Quail MA, Kieser H, Harper D, Bateman A, Brown S, Chandra G, Chen CW, Collins M, Cronin A, Fraser A, Goble A, Hidalgo J, Hornsby T, Howarth S, Huang CH, Kieser T, Larke L, Murphy L, Oliver K, O'Neil S, Rabinowitsch E, Rajandream MA, Rutherford K, Rutter S, Seeger K, Saunders D, Sharp S, Squares R, Squares S, Taylor K, Warren T, Wietzorrek A, Woodward J, Barrell BG, Parkhill J, Hopwood DA (2002) Complete genome sequence of the model actinomycete *Streptomyces coelicolor* A3(2). *Nature* 417:141–147
15. Bérty J (2005) Bioactive microbial metabolites. *J Antibiot (Tokyo)* 58:1–26
16. Bibb MJ (2005) Regulation of secondary metabolism in streptomycetes. *Curr Opin Microbiol* 8:208–215
17. Bibb MJ, Hesketh A (2009) Chapter 4. Analyzing the regulation of antibiotic production in streptomycetes. *Methods Enzymol* 458:93–116
18. Birko Z, Bialek S, Buzas K, Szajli E, Traag BA, Medzihradszky KF, Rigali S, Vijgenboom E, Penyige A, Kele Z, van Wezel GP, Biro S (2007) The secreted signaling protein factor C triggers the A-factor response regulon in *Streptomyces griseus*: overlapping signaling routes. *Mol Cell Proteomics* 6:1248–1256
19. Biro S, Bekesi I, Vitalis S, Szabo G (1980) A substance effecting differentiation in *Streptomyces griseus*. Purification and properties. *Eur J Biochem* 103:359–363
20. Biro S, Birko Z, van Wezel GP (2000) Transcriptional and functional analysis of the gene for factor C, an extracellular signal protein involved in cytodifferentiation of *Streptomyces griseus*. *Antonie Van Leeuwenhoek* 78:277–285
21. Bok JW, Chiang YM, Szewczyk E, Reyes-Dominguez Y, Davidson AD, Sanchez JF, Lo HC, Watanabe K, Strauss J, Oakley BR, Wang CC, Keller NP (2009) Chromatin-level regulation of biosynthetic gene clusters. *Nat Chem Biol* 5:462–464
22. Brückner R, Titgemeyer F (2002) Carbon catabolite repression in bacteria: choice of the carbon source and autoregulatory limitation of sugar utilization. *FEMS Microbiol Lett* 209:141–148
23. Caboche S, Pupin M, Leclerc V, Fontaine A, Jacques P, Kuchero G (2008) NORINE: a database of nonribosomal peptides. *Nucleic Acids Res* 36:D326–D331
24. Carter RA, Worsley PS, Sawers G, Challis GL, Dilworth MJ, Carson KC, Lawrence JA, Wexler M, Johnston AW, Yeoman KH (2002) The *vbs* genes that direct synthesis of the siderophore vibriobactin in *Rhizobium leguminosarum*: their expression in other genera requires ECF sigma factor RpoI. *Mol Microbiol* 44:1153–1166
25. Challis GL, Hopwood DA (2003) Synergy and contingency as driving forces for the evolution of multiple secondary metabolite production by *Streptomyces* species. *Proc Natl Acad Sci USA* 100:14555–14561
26. Charusanti P, Fong NL, Nagarajan H, Pereira AR, Li HJ, Abate EA, Su Y, Gerwick WH, Palsson BO (2012) Exploiting adaptive laboratory evolution of *Streptomyces clavuligerus* for antibiotic discovery and overproduction. *PLoS One* 7:e33727
27. Chater KF (2006) *Streptomyces* inside-out: a new perspective on the bacteria that provide us with antibiotics. *Philosophical Transactions of the Royal Society of London. Ser B Biol Sci* 361:761–768
28. Chuanchuen R, Schweizer HP (2012) Global transcriptional responses to triclosan exposure in *Pseudomonas aeruginosa*. *Int J Antimicrob Agents* 40:114–122
29. Colson S, Stephan J, Hertrich T, Saito A, van Wezel GP, Titgemeyer F, Rigali S (2007) Conserved *cis*-acting elements upstream of genes composing the chitinolytic system of streptomycetes are DasR-responsive elements. *J Mol Microbiol Biotechnol* 12:60–66
30. Colson S, van Wezel GP, Craig M, Noens EE, Nothhaft H, Mommaas AM, Titgemeyer F, Joris B, Rigali S (2008) The chitinase-binding protein, DasA, acts as a link between chitin utilization and morphogenesis in *Streptomyces coelicolor*. *Microbiology* 154:373–382
31. Corre C, Song L, O'Rourke S, Chater KF, Challis GL (2008) 2-Alkyl-4-hydroxymethylfuran-3-carboxylic acids, antibiotic production inducers discovered by *Streptomyces coelicolor* genome mining. *Proc Natl Acad Sci USA* 105:17510–17515
32. Craig M, Lambert S, Jourdan S, Tenconi E, Colson S, Maciejewska M, Martin JF, Ongena M, van Wezel G, Rigali S (2012) Unsuspected control of siderophore production by *N*-acetylglucosamine in streptomycetes. *Environ Microbiol Rep* 4:512–521
33. Craney A, Ozimok C, Pimentel-Elardo SM, Capretta A, Nodwell JR (2012) Chemical perturbation of secondary metabolism demonstrates important links to primary metabolism. *Chem Biol* 19:1020–1027
34. D'Alia D, Eggle D, Nieselt K, Hu WS, Breitling R, Takano E (2011) Deletion of the signalling molecule synthase ScbA has pleiotropic effects on secondary metabolite biosynthesis, morphological differentiation and primary metabolism in *Streptomyces coelicolor* A3(2). *Microb Biotechnol* 4:239–251
35. de Jong A, van Heel AJ, Kok J, Kuipers OP (2010) BAGEL2: mining for bacteriocins in genomic data. *Nucleic Acids Res* 38:W647–W651
36. Demain AL (1989) Carbon source regulation of idiolite biosynthesis in regulation of secondary metabolism in actinomycetes. *CRC Press, Boca Raton*, pp 127–134
37. Demain AL (1999) Pharmaceutically active secondary metabolites of microorganisms. *Appl Microbiol Biotechnol* 52:455–463
38. Dobretsov S, Dahms HU, Yili H, Wahl M, Qian PY (2007) The effect of quorum-sensing blockers on the formation of marine microbial communities and larval attachment. *FEMS Microbiol Ecol* 60:177–188
39. Dulaney EL (1948) Observations on *Streptomyces griseus*: II. Nitrogen sources for growth and streptomycin production. *J Bacteriol* 56:305–313

40. Fedorova D, Muktali V, Medema H (2012) Bioinformatics approaches and software for detection of secondary metabolic gene clusters. In: Keller NP, Turner G (eds) Fungal secondary metabolism, vol. 944. Humana Press, New York, pp 23–45
41. Flärdh K, Buttner MJ (2009) *Streptomyces* morphogenetics: dissecting differentiation in a filamentous bacterium. *Nat Rev Microbiol* 7:36–49
42. Fleming A (1929) The antibacterial action of a *Penicillium*, with special reference to their use for the isolation of *B. influenzae*. *Brit J Exp Pathol* 10:226–236
43. Floriano B, Bibb M (1996) *afsR* is a pleiotropic but conditionally required regulatory gene for antibiotic production in *Streptomyces coelicolor* A3(2). *Mol Microbiol* 21:385–396
44. Goosen N, van de Putte P (1995) The regulation of transcription initiation by integration host factor. *Mol Microbiol* 16:1–7
45. Görke B, Stülke J (2008) Carbon catabolite repression in bacteria: many ways to make the most out of nutrients. *Nat Rev Microbiol* 6:613–624
46. Gross H (2009) Genomic mining—a concept for the discovery of new bioactive natural products. *Curr Opin Drug Discov Dev* 12:207–219
47. Gubbens J, Janus M, Florea BI, Overkleeft HS, van Wezel GP (2012) Identification of glucose kinase dependent and independent pathways for carbon control of primary metabolism, development and antibiotic production in *Streptomyces coelicolor* by quantitative proteomics. *Mol Microbiol* 86:1490–1507
48. Hara H, Ohnishi Y, Horinouchi S (2009) DNA microarray analysis of global gene regulation by A-factor in *Streptomyces griseus*. *Microbiology* 155:2197–2210
49. Hiard S, Maree R, Colson S, Hoskisson PA, Titgemeyer F, van Wezel GP, Joris B, Wehenkel L, Rigali S (2007) PREDetector: a new tool to identify regulatory elements in bacterial genomes. *Biochem Biophys Res Commun* 357:861–864
50. Hirano S, Tanaka K, Ohnishi Y, Horinouchi S (2008) Conditionally positive effect of the TetR-family transcriptional regulator AtrA on streptomycin production by *Streptomyces griseus*. *Microbiology* 154:905–914
51. Hopwood DA (1999) Forty years of genetics with *Streptomyces*: from in vivo through in vitro to in silico. *Microbiology* 145:2183–2202
52. Hopwood DA (2006) Soil to genomics: the *Streptomyces* chromosome. *Annu Rev Genet* 40:1–23
53. Hopwood DA (2007) *Streptomyces* in nature and medicine: the antibiotic makers. Oxford University Press, New York
54. Horinouchi S, Beppu T (1992) Autoregulatory factors and communication in *actinomycetes*. *Annu Rev Microbiol* 46:377–398
55. Horinouchi S, Beppu T (1994) A-factor as a microbial hormone that controls cellular differentiation and secondary metabolism in *Streptomyces griseus*. *Mol Microbiol* 12:859–864
56. Hosaka T, Ohnishi-Kameyama M, Muramatsu H, Murakami K, Tsurumi Y, Kodani S, Yoshida M, Fujie A, Ochi K (2009) Antibacterial discovery in actinomycetes strains with mutations in RNA polymerase or ribosomal protein S12. *Nat Biotechnol* 27:462–464
57. Hsiao NH, Gottelt M, Takano E (2009) Chapter 6. Regulation of antibiotic production by bacterial hormones. *Methods Enzymol* 458:143–157
58. Huang J, Shi J, Molle V, Sohlberg B, Weaver D, Bibb MJ, Karoonuthaisiri N, Lih C-J, Kao CM, Buttner MJ, Cohen SJ (2005) Cross regulation among disparate antibiotic biosynthetic pathways of *Streptomyces coelicolor*. *Mol Microbiol* 58:1276–1287
59. Ikeda H, Ishikawa J, Hanamoto A, Shinose M, Kikuchi H, Shiba T, Sakaki Y, Hattori M, Omura S (2003) Complete genome sequence and comparative analysis of the industrial microorganism *Streptomyces avermitilis*. *Nat Biotechnol* 21:526–531
60. Inaoka T, Ochi K (2011) Scandium stimulates the production of amylase and bacilysin in *Bacillus subtilis*. *Appl Environ Microbiol* 77:8181–8183
61. Inaoka T, Takahashi K, Yada H, Yoshida M, Ochi K (2004) RNA polymerase mutation activates the production of a dormant antibiotic 3,3'-neotrehalosadiamine via an autoinduction mechanism in *Bacillus subtilis*. *J Biol Chem* 279:3885–3892
62. Iqbal M, Mast Y, Amin R, Hodgson DA, Wohlleben W, Burroughs NJ (2012) Extracting regulator activity profiles by integration of de novo motifs and expression data: characterizing key regulators of nutrient depletion responses in *Streptomyces coelicolor*. *Nucleic Acids Res* 40:5227–5239
63. Johansen SK, Maus CE, Plikaytis BB, Douthwaite S (2006) Capreomycin binds across the ribosomal subunit interface using tlyA-encoded 2'-O-methylations in 16S and 23S rRNAs. *Mol Cell* 23:173–182
64. Jornvall H, Hedlund J, Bergman T, Oppermann U, Persson B (2010) Superfamilies SDR and MDR: from early ancestry to present forms. Emergence of three lines, a Zn-metalloenzyme, and distinct variabilities. *Biochem Biophys Res Commun* 396:125–130
65. Kato JY, Funa N, Watanabe H, Ohnishi Y, Horinouchi S (2007) Biosynthesis of gamma-butyrolactone autoregulators that switch on secondary metabolism and morphological development in *Streptomyces*. *Proc Natl Acad Sci USA* 104:2378–2383
66. Kawachi R, Akashi T, Kamitani Y, Sy A, Wangchaisoonthorn U, Nihira T, Yamada Y (2000) Identification of an AfsA homologue (BarX) from *Streptomyces virginiae* as a pleiotropic regulator controlling autoregulator biosynthesis, virginiamycin biosynthesis and virginiamycin M1 resistance. *Mol Microbiol* 36:302–313
67. Kawai K, Wang G, Okamoto S, Ochi K (2007) The rare earth, scandium, causes antibiotic overproduction in *Streptomyces* spp. *FEMS Microbiol Lett* 274:311–315
68. Kersten RD, Yang YL, Xu Y, Cimermanic P, Nam SJ, Fenical W, Fischbach MA, Moore BS, Dorrestein PC (2011) A mass spectrometry-guided genome mining approach for natural product peptidogenomics. *Nat Chem Biol* 7:794–802
69. Kitani S, Yamada Y, Nihira T (2001) Gene replacement analysis of the butyrolactone autoregulator receptor (FarA) reveals that FarA acts as a novel regulator in secondary metabolism of *Streptomyces lavendulae* FRI-5. *J Bacteriol* 183:4357–4363
70. Klevens RM, Morrison MA, Nadle J, Petit S, Gershman K, Ray S, Harrison LH, Lynfield R, Dumyati G, Townes JM, Craig AS, Zell ER, Fosheim GE, McDougal LK, Carey RB, Fridkin SK (2007) Invasive methicillin-resistant *Staphylococcus aureus* infections in the United States. *JAMA J Am Med Assoc* 298:1763–1771
71. Lahana R (1999) How many leads from HTS? *Drug Discov Today* 4:447–448
72. Laureti L, Song L, Huang S, Corre C, Leblond P, Challis GL, Aigle B (2011) Identification of a bioactive 51-membered macrolide complex by activation of a silent polyketide synthase in *Streptomyces ambofaciens*. *Proc Natl Acad Sci USA* 108:6258–6263
73. Lautru S, Challis GL (2004) Substrate recognition by nonribosomal peptide synthetase multi-enzymes. *Microbiology* 150:1629–1636
74. Lee J, Hwang Y, Kim S, Kim E, Choi C (2000) Effect of a global regulatory gene, *afsR2*, from *Streptomyces lividans* on avermectin production in *Streptomyces avermitilis*. *J Biosci Bioeng* 89:606–608
75. Lee PC, Umeyama T, Horinouchi S (2002) *afsS* is a target of AfsR, a transcriptional factor with ATPase activity that globally

- controls secondary metabolism in *Streptomyces coelicolor* A3(2). *Mol Microbiol* 43:1413–1430
76. Leipe DD, Landsman D (1997) Histone deacetylases, acetoin utilization proteins and acetylpolymine amidohydrolases are members of an ancient protein superfamily. *Nucleic Acids Res* 25:3693–3697
 77. Linares JF, Gustafsson I, Baquero F, Martinez JL (2006) Antibiotics as intermicrobial signaling agents instead of weapons. *Proc Natl Acad Sci USA* 103:19484–19489
 78. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (2001) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. *Adv Drug Deliv Rev* 46:3–26
 79. Liu G, Chater KF, Chandra G, Niu G, Tan H (2013) Molecular regulation of antibiotic biosynthesis in *Streptomyces*. *Microbiol Mol Biol Rev* 77:112–143
 80. Liu M, Kirpekar F, Van Wezel GP, Douthwaite S (2000) The tylosin resistance gene *tlrB* of *Streptomyces fradiae* encodes a methyltransferase that targets G748 in 23S rRNA. *Mol Microbiol* 37:811–820
 81. Maharjan S, Oh TJ, Lee HC, Sohng JK (2009) Identification and functional characterization of an *afsR* homolog regulatory gene from *Streptomyces venezuelae* ATCC 15439. *J Microbiol Biotechnol* 19:121–127
 82. Malpartida F, Hopwood DA (1986) Physical and genetic characterisation of the gene cluster for the antibiotic actinorhodin in *Streptomyces coelicolor* A3(2). *Mol Gen Genet* 205:66–73
 83. Manteca A, Fernandez M, Sanchez J (2005) A death round affecting a young compartmentalized mycelium precedes aerial mycelium dismantling in confluent surface cultures of *Streptomyces antibioticus*. *Microbiology* 151:3689–3697
 84. Mao X, Cai T, Olyarchuk JG, Wei L (2005) Automated genome annotation and pathway identification using the KEGG Orthology (KO) as a controlled vocabulary. *Bioinformatics* 21:3787–3793
 85. Martín JF (2004) Phosphate control of the biosynthesis of antibiotics and other secondary metabolites is mediated by the PhoR-PhoP system: an unfinished story. *J Bacteriol* 186:5197–5201
 86. Martín JF, Demain A (1980) Control of antibiotic biosynthesis. *Microbiol Rev* 44:230–251
 87. Martin JF, Aparicio JF (2009) Enzymology of the polyenes pimarin and candicidin biosynthesis. *Methods Enzymol* 459:215–242
 88. Martin JF, Liras P (2010) Engineering of regulatory cascades and networks controlling antibiotic biosynthesis in *Streptomyces*. *Curr Opin Microbiol* 13:263–273
 89. Martin JF, Sola-Landa A, Santos-Beneit F, Fernandez-Martinez LT, Prieto C, Rodriguez-Garcia A (2011) Cross-talk of global nutritional regulators in the control of primary and secondary metabolism in *Streptomyces*. *Microb Biotechnol* 4:165–174
 90. Martinez A, Kolvek SJ, Hopke J, Yip CL, Osburne MS (2005) Environmental DNA fragment conferring early and increased sporulation and antibiotic production in *Streptomyces* species. *Appl Environ Microbiol* 71:1638–1641
 91. Matsumoto A, Ishizuka H, Beppu T, Horinouchi S (1995) Involvement of a small ORF downstream of the *afsR* gene in the regulation of secondary metabolism in *Streptomyces coelicolor* A3(2). *Actinomycetologica* 9:37–43
 92. McDowall KJ, Thamchaipenet A, Hunter IS (1999) Phosphate control of oxytetracycline production by *Streptomyces rimosus* is at the level of transcription from promoters overlapped by tandem repeats similar to those of the DNA-binding sites of the *OmpR* family. *J Bacteriol* 181:3025–3032
 93. Medema M, Blin K, Cimermancic P, de Jager V, Zakrzewski P, Fischbach MA, Weber T, Takano E, Breitling R (2011) anti-SMASH: rapid identification, annotation and analysis of secondary metabolite biosynthesis gene clusters in bacterial and fungal genome sequences. *Nucleic Acids Res* 39:W339–W346
 94. Medema MH, Breitling R, Bovenberg R, Takano E (2011) Exploiting plug-and-play synthetic biology for drug discovery and production in microorganisms. *Nat Rev Microbiol* 9:131–137
 95. Mendes MV, Tunca S, Anton N, Recio E, Sola-Landa A, Aparicio JF, Martin JF (2007) The two-component *phoR-phoP* system of *Streptomyces natalensis*: inactivation or deletion of *phoP* reduces the negative phosphate regulation of pimarin biosynthesis. *Metab Eng* 9:217–227
 96. Moore JM, Bradshaw E, Seipke RF, Hutchings MI, McArthur M (2012) Use and discovery of chemical elicitors that stimulate biosynthetic gene clusters in *Streptomyces* bacteria. *Methods Enzymol* 517:367–385
 97. Myers PL (1997) Will combinatorial chemistry deliver real medicines? *Curr Opin Biotechnol* 8:701–707
 98. Nazari B, Kobayashi M, Saito A, Hassaninasab A, Miyashita K, Fujii T (2012) Chitin-induced gene expression involved in secondary metabolic pathways in *Streptomyces coelicolor* A3(2) grown in soil. *Appl Environ Microbiol* 79:707–713
 99. Nett M, Ikeda H, Moore BS (2009) Genomic basis for natural product biosynthetic diversity in the actinomycetes. *Nat Prod Rep* 26:1362–1384
 100. Newman DJ, Cragg GM (2007) Natural products as sources of new drugs over the last 25 years. *J Nat Prod* 70:461–477
 101. Nodwell JR, Losick R (1998) Purification of an extracellular signaling molecule involved in production of the aerial mycelium by *Streptomyces coelicolor*. *J Bacteriol* 180:1334–1337
 102. Nothaft H, Dresel D, Willimek A, Mahr K, Niederweis M, Titgemeyer F (2003) The phosphotransferase system of *Streptomyces coelicolor* is biased for *N*-acetylglucosamine metabolism. *J Bacteriol* 185:7019–7023
 103. Nothaft H, Rigali S, Boomsma B, Swiatek M, McDowall KJ, van Wezel GP, Titgemeyer F (2010) The permease gene *nagE2* is the key to *N*-acetylglucosamine sensing and utilization in *Streptomyces coelicolor* and is subject to multi-level control. *Mol Microbiol* 75:1133–1144
 104. Novakova R, Rehakova A, Kutas P, Feckova L, Kormanec J (2011) The role of two SARP family transcriptional regulators in regulation of the auricin gene cluster in *Streptomyces aureofaciens* CCM 3239. *Microbiology* 157:1629–1639
 105. O'Rourke S, Wietzorrek A, Fowler K, Corre C, Challis GL, Chater KF (2009) Extracellular signalling, translational control, two repressors and an activator all contribute to the regulation of methylenomycin production in *Streptomyces coelicolor*. *Mol Microbiol* 71:763–778
 106. Ochi K, Hosaka T (2013) New strategies for drug discovery: activation of silent or weakly expressed microbial gene clusters. *Appl Microbiol Biotechnol* 97:87–98
 107. Ochi K, Okamoto S (2012) A magic bullet for antibiotic discovery. *Chem Biol* 19:932–934
 108. Ochi K, Tanaka Y, Tojo S (2013) Activating the expression of bacterial cryptic genes by *rpoB* mutations in RNA polymerase or by rare earth elements. *J Ind Microbiol Biotechnol* (submitted)
 109. Ohnishi Y, Ishikawa J, Hara H, Suzuki H, Ikenoya M, Ikeda H, Yamashita A, Hattori M, Horinouchi S (2008) Genome sequence of the streptomycin-producing microorganism *Streptomyces griseus* IFO 13350. *J Bacteriol* 190:4050–4060
 110. Ohnishi Y, Kameyama S, Onaka H, Horinouchi S (1999) The A-factor regulatory cascade leading to streptomycin biosynthesis in *Streptomyces griseus*: identification of a target gene of the A-factor receptor. *Mol Microbiol* 34:102–111

111. Oliynyk M, Samborsky M, Lester JB, Mironenko T, Scott N, Dickens S, Haydock SF, Leadlay PF (2007) Complete genome sequence of the erythromycin-producing bacterium *Saccharopolyspora erythraea* NRRL23338. *Nat Biotechnol* 25:447–453
112. Omura S, Ikeda H, Ishikawa J, Hanamoto A, Takahashi C, Shinose M, Takahashi Y, Horikawa H, Nakazawa H, Osonoe T, Kikuchi H, Shiba T, Sakaki Y, Hattori M (2001) Genome sequence of an industrial microorganism *Streptomyces avermitilis*: deducing the ability of producing secondary metabolites. *Proc Natl Acad Sci USA* 98:12215–12220
113. Onaka H, Mori Y, Igarashi Y (2011) Mycolic acid-containing bacteria induce natural-product biosynthesis in *Streptomyces* species. *Appl Environ Microbiol* 77:400–406
114. Paradkar A (2013) Clavulanic acid production by *Streptomyces clavuligerus*: biogenesis, regulation and strain improvement. *J Antibiot*. doi:10.1038/ja.2013.26
115. Parajuli N, Viet HT, Ishida K, Tong HT, Lee HC, Liou K, Sohng JK (2005) Identification and characterization of the *afsR* homologue regulatory gene from *Streptomyces peucetius* ATCC 27952. *Res Microbiol* 156:707–712
116. Pawlik K, Kotowska M, Chater KF, Kuczek K, Takano E (2007) A cryptic type I polyketide synthase (*cpk*) gene cluster in *Streptomyces coelicolor* A3(2). *Arch Microbiol* 187:87–99
117. Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL (2007) Drugs for bad bugs: confronting the challenges of antibacterial discovery. *Nat Rev Drug Discov* 6:29–40
118. Piepersberg W, Distler J (1997) Aminoglycosides and sugar components in other secondary metabolites. In: Rehm HJ, Reed G (eds) *Products of secondary metabolism*, vol. 7, 2nd edn. VCH-Verlagsgesellschaft, Weinheim, pp 397–488
119. Pimm SL, Russell GJ, Gittleman JL, Brooks TM (1995) The future of biodiversity. *Science* 269:347–350
120. Qiu X, Yan X, Liu M, Han R (2012) Genetic and proteomic characterization of *rpoB* mutations and their effect on nematocidal activity in *Photobacterium luminescens* LN2. *PLoS One* 7:e43114
121. Ratcliff WC, Denison RF (2011) Microbiology. Alternative actions for antibiotics. *Science* 332:547–548
122. Reading C, Cole M (1977) Clavulanic acid: a beta-lactamase-inhibiting beta-lactam from *Streptomyces clavuligerus*. *Antimicrob Agents Chemother* 11:852–857
123. Recio E, Colinas A, Rumero A, Aparicio JF, Martín JF (2004) PI factor, a novel type quorum-sensing inducer elicits pimarin production in *Streptomyces natalensis*. *J Biol Chem* 279:41586–41593
124. Rigali S, Nothhaft H, Noens EE, Schlicht M, Colson S, Muller M, Joris B, Koerten HK, Hopwood DA, Titgemeyer F, van Wezel GP (2006) The sugar phosphotransferase system of *Streptomyces coelicolor* is regulated by the GntR-family regulator DasR and links *N*-acetylglucosamine metabolism to the control of development. *Mol Microbiol* 61:1237–1251
125. Rigali S, Titgemeyer F, Barends S, Mulder S, Thomae AW, Hopwood DA, van Wezel GP (2008) Feast or famine: the global regulator DasR links nutrient stress to antibiotic production by *Streptomyces*. *EMBO Rep* 9:670–675
126. Rodriguez-Garcia A, Sola-Landa A, Apel K, Santos-Beneit F, Martín JF (2009) Phosphate control over nitrogen metabolism in *Streptomyces coelicolor*: direct and indirect negative control of *glnR*, *glnA*, *glnII* and *amtB* expression by the response regulator PhoP. *Nucleic Acids Res* 37:3230–3242
127. Romero D, Traxler MF, Lopez D, Kolter R (2011) Antibiotics as signal molecules. *Chem Rev* 111:5492–5505
128. Sanchez S, Chavez A, Forero A, Garcia-Huante Y, Romero A, Sanchez M, Rocha D, Sanchez B, Avalos M, Guzman-Trampe S, Rodriguez-Sanoja R, Langley E, Ruiz B (2010) Carbon source regulation of antibiotic production. *J Antibiot (Tokyo)* 63:442–459
129. Santos-Beneit F, Barriuso-Iglesias M, Fernandez-Martinez LT, Martinez-Castro M, Sola-Landa A, Rodriguez-Garcia A, Martín JF (2011) The RNA polymerase omega factor RpoZ is regulated by PhoP and has an important role in antibiotic biosynthesis and morphological differentiation in *Streptomyces coelicolor*. *Appl Environ Microbiol* 77:7586–7594
130. Santos-Beneit F, Rodriguez-Garcia A, Sola-Landa A, Martín JF (2009) Cross-talk between two global regulators in *Streptomyces*: PhoP and AfsR interact in the control of *afsS*, *pstS* and *phoRP* transcription. *Mol Microbiol* 72:53–68
131. Sekurova O, Sletta H, Ellingsen TE, Valla S, Zotchev S (1999) Molecular cloning and analysis of a pleiotropic regulatory gene locus from the nystatin producer *Streptomyces noursei* ATCC11455. *FEMS Microbiol Lett* 177:297–304
132. Shapiro S (1989) Nitrogen assimilation in *actinomycetes* and the influence of nitrogen nutrition on *actinomycete* secondary metabolism. In: Shapiro S (ed) *Regulation of secondary metabolism in actinomycetes*. CRC Press, Boca Raton, pp 135–211
133. Sidda JD, Corre C (2012) Gamma-butyrolactone and furan signaling systems in *Streptomyces*. *Methods Enzymol* 517:71–87
134. Skinner R, Cundliffe E, Schmidt FJ (1983) Site of action of a ribosomal RNA methylase responsible for resistance to erythromycin and other antibiotics. *J Biol Chem* 258:12702–12706
135. Sola-Landa A, Moura RS, Martín JF (2003) The two-component PhoR-PhoP system controls both primary metabolism and secondary metabolite biosynthesis in *Streptomyces lividans*. *Proc Natl Acad Sci USA* 100:6133–6138
136. Sola-Landa A, Moura RS, Martín JF (2002) The two-component PhoR-PhoP system controls both primary metabolism and secondary metabolite biosynthesis in *Streptomyces lividans*. *Proc Natl Acad Sci USA* 100:6133–6138
137. Sterner DE, Berger SL (2000) Acetylation of histones and transcription-related factors. *Microbiol Mol Biol Rev* 64:435–459
138. Strauss J, Reyes-Dominguez Y (2011) Regulation of secondary metabolism by chromatin structure and epigenetic codes. *Fungal Genet Biol* 48:62–69
139. Swiatek MA, Gubbens J, Bucca G, Song E, Yang YH, Laing E, Kim BG, Smith CP, van Wezel GP (2013) The ROK family regulator Rok7B7 pleiotropically affects xylose utilization, carbon catabolite repression, and antibiotic production in *Streptomyces coelicolor*. *J Bacteriol* 195:1236–1248
140. Swiatek MA, Tenconi E, Rigali S, van Wezel GP (2012) Functional analysis of the *N*-acetylglucosamine metabolic genes of *Streptomyces coelicolor* and role in the control of development and antibiotic production. *J Bacteriol* 194:1136–1144
141. Swiatek MA, Urem M, Tenconi E, Rigali S, van Wezel GP (2012) Engineering of *N*-acetylglucosamine metabolism for improved antibiotic production in *Streptomyces coelicolor* A3(2) and an unsuspected role of NagA in glucosamine metabolism. *Bioengineered* 3:280–285
142. Tamehiro N, Hosaka T, Xu J, Hu H, Otake N, Ochi K (2003) Innovative approach for improvement of an antibiotic-overproducing industrial strain of *Streptomyces albus*. *Appl Environ Microbiol* 69:6412–6417
143. Tanaka Y, Hosaka T, Ochi K (2010) Rare earth elements activate the secondary metabolite-biosynthetic gene clusters in *Streptomyces coelicolor* A3(2). *J Antibiot* 63:477–481
144. Tanaka Y, Komatsu M, Okamoto S, Tokuyama S, Kaji A, Ikeda H, Ochi K (2009) Antibiotic overproduction by *rpsL* and *rsmG* mutants of various actinomycetes. *Appl Environ Microbiol* 75:4919–4922

145. Titgemeyer F (2007) Carbon and nitrogen regulation in Gram-positive bacteria: a tribute to Milton H. Saier, Jr. *J Mol Microbiol Biotechnol* 12:5–8
146. Titgemeyer F, Reizer J, Reizer A, Saier MH Jr (1994) Evolutionary relationships between sugar kinases and transcriptional repressors in bacteria. *Microbiology* 140:2349–2354
147. Udway DW, Zeigler L, Asolkar RN, Singan V, Lapidus A, Fenical W, Jensen PR, Moore BS (2007) Genome sequencing reveals complex secondary metabolome in the marine actinomycete *Salinispora tropica*. *Proc Natl Acad Sci USA* 104:10376–10381
148. Uguru GC, Stephens KE, Stead JA, Towle JE, Baumberg S, McDowall KJ (2005) Transcriptional activation of the pathway-specific regulator of the actinorhodin biosynthetic genes in *Streptomyces coelicolor*. *Mol Microbiol* 58:131–150
149. van Wezel GP, König M, Mahr K, Nothaft H, Thomae AW, Bibb M, Titgemeyer F (2007) A new piece of an old jigsaw: glucose kinase is activated posttranslationally in a glucose transport-dependent manner in *Streptomyces coelicolor* A3(2). *J Mol Microbiol Biotechnol* 12:67–74
150. van Wezel GP, Krabben P, Traag BA, Keijser BJ, Kerste R, Vijgenboom E, Heijnen JJ, Kraal B (2006) Unlocking *Streptomyces* spp. for use as sustainable industrial production platforms by morphological engineering. *Appl Environ Microbiol* 72:5283–5288
151. van Wezel GP, McDowall KJ (2011) The regulation of the secondary metabolism of *Streptomyces*: new links and experimental advances. *Nat Prod Rep* 28:1311–1333
152. van Wezel GP, McKenzie NL, Nodwell JR (2009) Chapter 5. Applying the genetics of secondary metabolism in model actinomycetes to the discovery of new antibiotics. *Methods Enzymol* 458:117–141
153. van Wezel GP, Titgemeyer F, Rigali S (2006) Methods and means for metabolic engineering and improved product formation by micro-organisms Patent application WO/2007/094667
154. van Wezel GP, White J, Hoogvliet G, Bibb MJ (2000) Application of *redD*, the transcriptional activator gene of the undecylprodigiosin biosynthetic pathway, as a reporter for transcriptional activity in *Streptomyces coelicolor* A3(2) and *Streptomyces lividans*. *J Mol Microbiol Biotechnol* 2:551–556
155. Vigliotta G, Tredici SM, Damiano F, Montinaro MR, Pulimeno R, di Summa R, Massardo DR, Gnoni GV, Alifano P (2005) Natural merodiploidy involving duplicated *rpoB* alleles affects secondary metabolism in a producer actinomycete. *Mol Microbiol* 55:396–412
156. Vining LC (1992) Secondary metabolism, inventive evolution and biochemical diversity: a review. *Gene* 115:135–140
157. Vogtli M, Chang PC, Cohen SN (1994) afsR2: a previously undetected gene encoding a 63-amino-acid protein that stimulates antibiotic production in *Streptomyces lividans*. *Mol Microbiol* 14:643–653
158. Watrous J, Roach P, Alexandrov T, Heath BS, Yang JY, Kersten RD, van der Voort M, Pogliano K, Gross H, Raaijmakers JM, Moore BS, Laskin J, Bandeira N, Dorrestein PC (2012) Mass spectral molecular networking of living microbial colonies. *Proc Natl Acad Sci USA* 109:E1743–E1752
159. WHO-Media-centre (2012) Antimicrobial resistance WHO. <http://www.who.int/mediacentre/factsheets/fs194/en/>
160. Wietzorrek AM, Bibb (1997) A novel family of proteins that regulates antibiotic production in *Streptomyces* appears to contain an OmpR-like DNA-binding fold. *Mol Microbiol* 25:1181–1184
161. Willey JM, Gaskell AA (2011) Morphogenetic signaling molecules of the streptomycetes. *Chem Rev* 111:174–187
162. Woodruff HB, Ruger M (1948) Studies on the physiology of a streptomycin-producing strain of *Streptomyces griseus* on proline medium. *J Bacteriol* 56:315–321
163. Xu Q, van Wezel GP, Chiu HJ, Jaroszewski L, Klock HE, Knuth MW, Miller MD, Lesley SA, Godzik A, Elsliger MA, Deacon AM, Wilson IA (2012) Structure of an MmyB-like regulator from *C. aurantiacus*, member of a new transcription factor family linked to antibiotic metabolism in actinomycetes. *PLoS One* 7:e41359
164. Yamada Y, Nihira T (1999) Microbial hormones and microbial chemical ecology. In: Mori K (ed) *Comprehensive natural products chemistry*, vol. 8. Elsevier Scientific Publishers, Dordrecht, pp 377–413
165. Yamamoto S, He Y, Arakawa K, Kinashi H (2008) γ -Butyrolactone-dependent expression of the streptomyces antibiotic regulatory protein gene *srrY* plays a central role in the regulatory cascade leading to Lankacidin and lankamycin production in *Streptomyces rochei*. *J Bacteriol* 190:1308–1316
166. Yang YH, Song E, Willemse J, Park SH, Kim WS, Kim EJ, Lee BR, Kim JN, van Wezel GP, Kim BG (2012) A novel function of *Streptomyces* integration host factor (slHF) in the control of antibiotic production and sporulation in *Streptomyces coelicolor*. *Antonie Van Leeuwenhoek* 101:479–492
167. Yang YL, Xu Y, Straight P, Dorrestein PC (2009) Translating metabolic exchange with imaging mass spectrometry. *Nat Chem Biol* 5:885–887
168. Yu Z, Zhu H, Dang F, Zhang W, Qin Z, Yang S, Tan H, Lu Y, Jiang W (2012) Differential regulation of antibiotic biosynthesis by DraR-K, a novel two-component system in *Streptomyces coelicolor*. *Mol Microbiol* 85:535–556
169. Zerikly M, Challis GL (2009) Strategies for the discovery of new natural products by genome mining. *Chembiochem: Eur J Chem Biol* 10:625–633